Journal article
Development of Hydrogels for Microneedle-Assisted Transdermal Delivery of Naloxone for Opioid-Induced Pruritus
Journal of pharmaceutical sciences, Vol.108(11), pp.3695-3703
11/2019
DOI: 10.1016/j.xphs.2019.08.025
PMCID: PMC6936750
PMID: 31476312
Abstract
Transdermal naloxone delivery could be a potential option for treating opioid-induced pruritus, but naloxone does not permeate skin well because of its hydrophilic nature. Microneedles (MNs) could overcome the skin barrier by painlessly creating microchannels in the skin to permit naloxone absorption to therapeutic levels. This study investigated how ionization correlates with naloxone permeation across MN-treated skin. Hydrogels containing 0.2, 0.5, or 1% naloxone were formulated with 1% cross-linked polyacrylic acid (polymer) and adjusted to pH 5, 6.5, or 7.4. Porcine skin was treated with MNs and naloxone gel, and in vitro permeation studies were performed using an in-line diffusion setup. Gel structural properties were evaluated using rheology. All gels had viscoelastic properties and good spreadability. Naloxone permeation through intact skin was highest from pH 7.4 gels when naloxone is unionized, in contrast with undetectable concentrations permeated from pH 5 gels with 100% ionization. Combining MN treatment with pH 5 gels significantly enhanced permeation and resulted in steady-state flux that would achieve therapeutic delivery. Absorption lag time was affected by MN length and naloxone gel concentration. Polymer concentration did not influence drug permeability. This study demonstrates that transdermal naloxone delivery with MNs is a viable treatment option for opioid-induced pruritus.
Details
- Title: Subtitle
- Development of Hydrogels for Microneedle-Assisted Transdermal Delivery of Naloxone for Opioid-Induced Pruritus
- Creators
- Xinyi Gao - University of IowaNicole K. Brogden - University of Iowa Hospitals and Clinics
- Resource Type
- Journal article
- Publication Details
- Journal of pharmaceutical sciences, Vol.108(11), pp.3695-3703
- DOI
- 10.1016/j.xphs.2019.08.025
- PMID
- 31476312
- PMCID
- PMC6936750
- NLM abbreviation
- J Pharm Sci
- ISSN
- 0022-3549
- eISSN
- 1520-6017
- Publisher
- Elsevier Inc
- Grant note
- DOI: 10.13039/100000002, name: National Institutes of Health
- Language
- English
- Date published
- 11/2019
- Academic Unit
- Dermatology; Pharmaceutical Sciences and Experimental Therapeutics
- Record Identifier
- 9984296210902771
Metrics
12 Record Views